Dr. Phillip J. Koo spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Friday, November 14, 2014 on “Utility of NaF PET/CT and Other Diagnostic Radiopharmaceuticals in Prostate Cancer.”
Keywords: diagnostic radiopharmaceuticals, prostate cancer, NaF, PET/CT[/su_tab]
How to cite: Koo, Phillip J. “Utility of NaF PET/CT and Other Diagnostic Radiopharmaceuticals in Prostate Cancer” Grand Rounds in Urology. July 21, 2015. Accessed Nov 2024. https://dev.grandroundsinurology.com/prostate-cancer-phillip-j-koo-diagnostic-radiopharmaceuticals/.
References
Buchegger F, Garibotto V, Zilli T, et al. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):68-78.
http://www.ncbi.nlm.nih.gov/pubmed/24104592
Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S36-40.
http://www.ncbi.nlm.nih.gov/pubmed/23579864
Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006 Feb;47(2):287-97.
http://www.ncbi.nlm.nih.gov/pubmed/16455635
Goldstein J, Even-Sapir E, Ben-Haim S, et al. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure? Am J Clin Oncol. 2014 Nov 4.
http://www.ncbi.nlm.nih.gov/pubmed/25319322
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
http://www.ncbi.nlm.nih.gov/pubmed/10647931
Hillman BJ, Frank RA, Abraham BC. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for Medicare Coverage of New PET Radiopharmaceuticals. J Nucl Med. 2013 Sep;54(9):1675-9.
http://www.ncbi.nlm.nih.gov/pubmed/23907756
Hillner BE, Siegel BA, Hanna L, et al. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. J Nucl Med. 2014 Jul;55(7):1054-61
http://www.ncbi.nlm.nih.gov/pubmed/24819422
Kelloff GJ, Choyke P, Coffey DS, et al. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol. 2009 Jun;192(6):1455-70.
http://www.ncbi.nlm.nih.gov/pubmed/19457806
Merdan S, Womble PR, Miller DC, et al. Toward Better Use of Bone Scans Among Men With Early-stage Prostate Cancer. Urology. 2014 Oct;84(4):793-8.
http://www.ncbi.nlm.nih.gov/pubmed/25096341
Tateishi U, Morita S, Taguri M, et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010 Aug;24(7):523-31.
http://www.ncbi.nlm.nih.gov/pubmed/20559896
von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014 Mar;35(3):221-30.
http://www.ncbi.nlm.nih.gov/pubmed/24240194
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology and the American Board of Nuclear Medicine. Dr. Koo is an active member of multiple societies and has served as the Chair of Nuclear Medicine for the RSNA Scientific Program Committee, Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and Chair of the Prostate Cancer Working Group at the SNMMI. Dr. Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, the European Journal of Nuclear Medicine and Molecular Imaging, Urology, and the Journal of the American College of Radiology.
